Cancer is the second-largest peptide drug indication after obesity-and-metabolic, and it covers more chemistry diversity. Peptide-drug conjugates, peptide cancer vaccines, peptide receptor radionuclide therapy (PRRT), and tumor-targeting macrocyclic peptides all land here.
The most discussed 2026 thread outside trial readouts: a 21-expert panel proposed a 5,000-participant, decade-long randomized trial to test whether semaglutide and tirzepatide prevent obesity-related cancers. The proposal sits alongside Mordor Intelligence's $49.68B-to-$70.2B (2026–2031) peptide therapeutics market projection, much of it driven by oncology.
Stories here cover trial readouts, AACR and ASCO presentations, and the cancer-prevention angle on GLP-1s. See #oncology, #peptide-vaccine, #peptide-drug-conjugate, and #breast-cancer.
Researchers at Beijing University of Chinese Medicine and the China Academy of Chinese Medical Sciences coated curcumin-loaded ZIF-90 nanoparticles with a PEG-linked cell-penetrating peptide, CPP2, which increased uptake in colorectal cancer cells and accumulation in tumors. In mice, tumor suppression was 25.5% with curcumin alone, 48.5% with uncoated particles plus laser light, and 80.6% with peptide-coated particles plus light, the Drug Delivery paper reports. The work is preclinical.
Paige Gordon told NBC Bay Area she bought an injectable "Glow Stack" containing BPC-157 from a nurse who ran an Aptos med spa, in January and was not told of any risks; she had been diagnosed with breast cancer about two and a half years ago, and the disease was found again about two months ago. The report notes there is no conclusive evidence BPC-157 contributed to her recurrence, and that concerns about peptides and tumor growth remain theoretical. It also covers HHS's October 28 policy allowing limited compounding of BPC-157 and five other unapproved peptides, which the Partnership for Safe Medicines' Shabbir Imber Safdar said the public has mistaken for an FDA approval.
Using UT Southwestern health records from 2010 to July 2025, researchers emulated five target trials comparing adults with type 2 diabetes who started a GLP-1 drug with those who started another glucose-lowering drug, reporting in JAMA Network Open on November 3. Starting a GLP-1 drug was linked to a lower three-year risk of obesity-related cancer than insulin (hazard ratio 0.62) or sulfonylureas (0.67), mainly among patients with low diabetes severity; comparisons with metformin, DPP-4 inhibitors, and SGLT2 inhibitors showed no consistent difference. The study is observational, and the authors said the findings do not justify choosing a diabetes drug for cancer prevention.
Tongji University researchers used 365 nm UV light and a photoinitiator to polymerize a histidine-based monomer inside inflammatory breast cancer cells, forming peptide nanosheets about 30 nm thick that stiffened the cells, reduced their migration and invasion, and triggered a paraptosis-like cell death, they reported in ACS Nano. In mice with implanted tumors, light delivered through an optical fiber inhibited tumor growth by 72.2% without overt systemic toxicity; there is no human data.
Researchers at the First Affiliated Hospital of Henan University of Chinese Medicine reviewed 30 studies with 2,514 colorectal cancer patients, including 25 randomized trials, in which thymosin preparations were added to the same anticancer treatment, publishing in Frontiers in Oncology. After surgery, thymosin was linked to higher CD4 percentages, CD4/CD8 ratios, and natural killer cell percentages, and some trials reported better performance scores, but effects on neutropenia were inconclusive and only one trial gave comparable survival data. Certainty was low or very low, and the authors say current evidence does not support routine use.
Beijing University of Chemical Technology researchers coordinated copper ions with the dipeptide diphenylalanine to build nanospheres that generate reactive oxygen species under ultrasound, then loaded them with a PROTAC that degrades the cancer-linked proteins BRD3 and BRD4, reporting in Small. The combination with ultrasound killed 91.3% of HeLa cervical cancer cells in culture and inhibited tumor growth by 92.6% in tumor-bearing mice; there is no human data.
China Pharmaceutical University chemists reported in Organic Letters that capping a peptide's starting end with 4-mercaptoproline and cross-linking it to an internal cysteine holds short peptides in the helical shape needed to block protein-protein interactions inside cells. Tuning the cap's stereochemistry and the cross-linker improved helicity, cell uptake, resistance to breakdown, and binding to MDM2, and the peptides reduced cancer cell viability, growth, and migration in lab tests.
Researchers at Nanyang Technological University reported in ACS Nano on October 20, 2026 that peptides which separate into liquid droplets, called coacervates, can carry cargo into cells and release it when cathepsin B, an enzyme often overactive in cancer cells, cuts them. Standard cathepsin B cut sites borrowed from drug linkers worked poorly inside the dense droplets, but a newly designed four-amino-acid motif, FRFV, was cut efficiently and released cargo in cancer cells. The work is in the lab.
Researchers at Chi Mei Medical Center in Taiwan reported in Diabetology & Metabolic Syndrome on October 13, 2026 a records study in the TriNetX U.S. network that matched 176,981 women with overweight or obesity who started tirzepatide between 2022 and 2025 with the same number in lifestyle programs. Over up to two years, tirzepatide users had a lower rate of new endometrial cancer diagnoses (hazard ratio 0.717), a pattern seen across most subgroups. The authors said the observational, short-term findings do not establish that tirzepatide prevents the cancer.
Researchers at the Huntsman Cancer Institute and MD Anderson Cancer Center reported in JAMA Network Open on October 7, 2026 an analysis of 3,615 adults with diabetes in the 2024 National Health Interview Survey, representing 26.4 million U.S. adults. After adjustment, 20.5% of those with a cancer history used an injectable GLP-1 drug, compared with 26.5% of those without, a gap of 6.0 percentage points (adjusted odds ratio 0.70). The difference was not statistically significant when the analysis was limited to type 2 diabetes, and the authors said the survey cannot show whether the gap reflects eligibility, prescribing caution, patient choice, or access.
Eli Lilly's acquisition of Kelonia Therapeutics — announced April 20 with $3.25 billion upfront and up to $7 billion total including milestones — illustrates the company's broader pivot beyond GLP-1 weight-loss drugs. Kelonia develops in vivo CAR-T technology that reprograms patients' T-cells inside the body, eliminating the ex vivo cell-engineering step required by current CAR-T therapies. The deal joins Lilly's recent Centessa Pharmaceuticals (sleep) and Orna Therapeutics (cell therapy) acquisitions as part of a multi-vertical pipeline diversification. Transaction expected to close H2 2026.
A comprehensive review in Discover Oncology highlights antimicrobial peptides' emerging dual role as anticancer and antiviral therapeutics. AMPs selectively target cancer cell membranes through electrostatic interactions while also demonstrating antiviral activity, with their immunomodulatory properties and reduced resistance development offering advantages over conventional chemotherapy.
A comprehensive review in Journal of Nanobiotechnology positions peptide-drug conjugates (PDCs) as the next evolution beyond antibody-drug conjugates (ADCs) for targeted cancer therapy. Six PDCs are now in Phase III clinical trials with approximately 96 in development, offering advantages in tissue penetration, lower immunotoxicity, and more accessible manufacturing than ADCs.